Paradigm shift for people with Type 1 and Type 2 Diabetes

Clinical data demonstrate that islet cell transplantation is an effective treatment option for diabetic patients, particularly those with vascular complications.
 
 

Possible applications across multiple disease states and age groups.

Chrolich Biotech Brief history. Islet cells xenotransplantation. Technology description and theraputic applications.

Opportunity to Leapfrog ------

- While human pancreatic islet cell allo-transplantation is in experimental stage at the NIH today, islet cell xenotransplantation has already resulted in better health outcomes in the clinic ex-US. - Technology (methods and composition) patents have been granted in 21 countries including the United States.

Ready to learn more?

Getting in touch is easy. Use the form below and request a more info today.

Submitting Form...

The server encountered an error.

Form received.

- Timely transplantation of islet cell therapy in the complex treatment of DM significantly improves disease prognosis. - Prophylaxis, and regression of secondary diabetic complications achieved by repeat transplantations on regular basis. - Production of cultures of progenitor cells (regional stem cells) - Ensuring the maturation of the precursor cells to the state of actively-functioning beta cells. - Production of beta-cell cultures in sufficient amount to achieve long-term insulin independence for patients with T1DM, and without the need for immunosuppressive agents.

© 2017 . Chrolich Biotech . All Rights Reserved

- While human pancreatic islet cell allo-transplantation is in experimental stage at the NIH today, islet cell xenotransplantation has already resulted in better health outcomes in the clinic ex-US. - Technology (methods and composition) patents have been granted in 21 countries including the United States.
Getting in touch is easy. Use the form below and request a more info today.
Clinical data demonstrate that islet cell transplantation is an effective treatment option for diabetic patients, particularly those with vascular complications.
Chrolich Biotech Brief history. Islet cells xenotransplantation. Technology description and theraputic applications.
  • BRIEF HISTORY

     Brief history of Chrolich Biotech A privately-held, development-stage biotech company. Founded in 1992 by Dr. Vladislav Broytman and N.Skaletsky, in Moscow, Russian Federation. Established operations in the United States in 2004 in Philadelphia, Pennsylvania, and chaired by the founder’s son, Mr. Nick Broytman.
  • BENEFITS

     Technology benefits Enables verification of islet-cell function and sterility pre-transplantation to reduce the potential for immunogenicity Allows for the necessary number of subsequent transplants without the risk of cell rejection Facilitates transplant material accumulation platforms including the creation of a cryobank Possible applications across multiple disease states and age groups
  • INNOVATION

     Ahead of US based applications Chrolich’s islet cells xenotransplantation has demonstrated clinical benefits in patients with T1DM, and T2DM. While pancreatic islet auto-transplantation is an approved therapeutic procedure, following pancreatectomy for certain patients with pancreatitis, islet allo-tranplantation is currently in experimental stage only for T1DM by the US-National Institute of Diabetes, Digestive, and Kidney (NIDDK).
  • EFFICACY

     Efficacy Summary of Intramuscular Transplantation in T1DM Effect duration - 6.9 months Stabilization of labile forms of diabetes 20% to 30% reduction of insulin usage by 2/3 of patients Deceleration of disease progression Regression of secondary complications (neuropathy, retinopathy, nephropathy)
Getting in touch is easy. Use the form below and request a more info today.
- While human pancreatic islet cell allo-transplantation is in experimental stage at the NIH today, islet cell xenotransplantation has already resulted in better health outcomes in the clinic ex-US. - Technology (methods and composition) patents have been granted in 21 countries including the United States.
- While human pancreatic islet cell allo-transplantation is in experimental stage at the NIH today, islet cell xenotransplantation has already resulted in better health outcomes in the clinic ex-US. - Technology (methods and composition) patents have been granted in 21 countries including the United States.

Enables verification of islet-cell function.

Allows for the necessary number of subsequent transplants

Facilitates transplant material accumulation

Possible applications across multiple disease states and age groups

Getting in touch is easy. Use the form below and request a more info today.
- While human pancreatic islet cell allo-transplantation is in experimental stage at the NIH today, islet cell xenotransplantation has already resulted in better health outcomes in the clinic ex-US. - Technology (methods and composition) patents have been granted in 21 countries including the United States.